本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

PharmaCyte Biotech, Inc.

0.8900
-0.0274-2.99%
盤後0.89000.00000.00%19:50 EST
成交量:3.48萬
成交額:3.12萬
市值:604.82萬
市盈率:141.40
高:0.9174
開:0.9000
低:0.8800
收:0.9174
52周最高:1.94
52周最低:0.8000
股本:679.58萬
流通股本:607.75萬
量比:0.87
換手率:0.57%
股息:- -
股息率:- -
每股收益(TTM):0.0063
每股收益(LYR):3.19
淨資產收益率:-2.33%
總資產收益率:-4.29%
市淨率:0.14
市盈率(LYR):0.28

資料載入中...

2025/10/31

重要事件披露

Form 8-K - Current report
2025/09/15

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/09/05

重要事件披露

Form 8-K - Current report
2025/08/18

重要事件披露

Form 8-K - Current report
2025/08/09

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/04/24

重要事件披露

Form 8-K - Current report
2025/03/17

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/02/26

重要事件披露

Form 8-K - Current report
2024/12/13

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/12/04

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/13

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/17

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/13

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/05/31

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/02

重要事件披露

Form 8-K - Current report
2024/03/18

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/02/14

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/06

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/16

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]